Study of Ruxolitinib Cream in Children With Atopic Dermatitis

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
Incyte Corporation
Study ID
NCT05034822
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
2 Years - 11 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label maximum use trial to evaluate ruxolitinib safety, tolerability and blood levels after its topical application twice daily to affected areas (≥ 35% BSA) in pediatric participants with atopic dermatitis (AD) and to determine if its systemic bioavailability results in any adverse events.

Key Dates

Start date
Dec 16, 2021
Status verified
Sep 2023
Primary completion
Aug 7, 2023
Completion
Aug 7, 2023

Study Design

Enrollment
29 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib cream
    ruxolitinib 1.5% cream will be applied twice daily to all areas of the skin affected by AD

Primary Outcome Measure

Number of treatment-emergent adverse events [ Time Frame: Up to approximately 61 weeks ]

Locations (15)

FacilityCityStateZIPSite coordinators
Desert Sky DermatologyGilbertArizona85295-
Burke Pharmaceutical ResearchHot SpringsArkansas71913-
Orange County Research CenterAnaheimCalifornia92801-
Skin Care Research, Llc Scr HollywoodHollywoodFlorida33021-
Accel Clinical ResearchLake MaryFlorida32746-
San Marcus Research Clinic Inc.Miami LakesFlorida33014-
Forward Clinical TrialsTampaFlorida33624-
Advanced Medical Research PcSandy SpringsGeorgia30328-
Aeroallergy Research Lab of SavannahSavannahGeorgia31406-
Oakland Hills Dermatology PcAuburn HillsMichigan48326-
Skin Cancer and Dermatology InstituteRenoNevada89509-
Forest Hills Dermatology GroupForest HillsNew York11375-
Ohio Pediatric Research AssociationDaytonOhio45414-
Cyn3Rgy Research - Clinedge - PpdsGreshamOregon97030-
Progressive Clinical ResearchSan AntonioTexas78213-

Find similar trials in Gilbert, AZ

Related Studies